Cough medicine fights dyskinesias in Parkinson's

Nov 07, 2007

A cough suppressant and a drug tested as a schizophrenia therapy curb the involuntary movements that are disabling side effects of taking the Parkinson's disease medication levodopa, Portland scientists have found.

Dextromethorphan, used in such cold and flu medications as Robitussin, Sucrets, Triaminic and Vicks, suppresses dyskinesias in rats, researchers at Oregon Health & Science University and the Portland Veterans Affairs Medical Center found. Dyskinesias are the spastic or repetitive motions that result from taking levodopa, or L-dopa, over long periods.

The researchers also found that BMY-14802, a drug previously tested in people with schizophrenia and found to be safe – although not effective in treating schizophrenia symptoms – suppressed dyskinesias in rats more effectively than dextromethorphan did, suggesting that BMY-14802 might work to block dyskinesias in people with Parkinson's.

"These results were unexpected, but very exciting," said the study's lead author, Melanie A. Paquette, Ph.D., postdoctoral fellow in the Department of Behavioral Neuroscience, OHSU School of Medicine, and the PVAMC. "We have filed a patent for the use of BMY-14802 for dyskinesias and we hope to get funding to begin human trials very soon."

The study, titled "Differential effects of NMDA antagonists and sigma ligands on L-dopa-induced behavior in the hemiparkinson rat," is being presented during a poster session today at Neuroscience 2007, the 37th annual Society for Neuroscience conference in San Diego.

The results also affirm the value of the rat model for dyskinesias that Paquette's team used in the study. Previous studies by other researchers have shown the drug amantadine already is effective in treating dyskinesias in both humans and rats, and dextromethorphan's effectiveness against the condition in rats provides more data supporting the use of the model.

"Basically, these two drugs work to block dyskinesias in both humans and rats, and that means the rats are a good model to screen potential drug treatments for humans with dyskinesias," Paquette said.

But BMY-14802, which is an antagonist at sigma-1 receptor sites in the brain, "worked much better than dextromethorphan," an antagonist at N-methyl-D-aspartate (NMDA) receptors.

"There's something special about BMY-14802," Paquette explained. "The effect on dyskinesias is really striking and I've repeated it several times, so it's a reliable finding. It's a very exciting result."

Source: Oregon Health & Science University

Explore further: Hope in Liberia, anxiety in Mali as Ebola battle rages

add to favorites email to friend print save as pdf

Related Stories

Former Brown dean whose group won Nobel Prize dies

29 minutes ago

David Greer, a doctor who co-founded a group that won the 1985 Nobel Peace Prize for working to prevent nuclear war and who helped transform the medical school at Brown University, has died. He was 89.

'Call of Duty' blasts past $10 bn in sales

45 minutes ago

Blockbuster military shooter video game "Call of Duty" has blasted past $10 billion in lifetime sales, propelled by demand for the latest installment in the 11-year-old franchise.

Recommended for you

Mali announces new Ebola case

10 hours ago

Mali announced Saturday a new case of Ebola in a man who is fighting for his life in an intensive care unit in the capital Bamako.

Plague outbreak kills 40 in Madagascar: WHO

10 hours ago

An outbreak of plague has killed 40 people in Madagascar, the World Health Organization said, warning that the disease could spread rapidly in the country's densely populated capital Antananarivo.

UN chief: Ebola cases in Mali a 'deep concern'

Nov 21, 2014

The United Nations chief warned Friday that Ebola may be easing in part of West Africa but is still hitting hard in other areas and outpacing the international response.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.